Pharmaceutical Executive, May 2022 Issue (PDF)

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and profitability.

LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.

Top-line results from two pivotal Phase III trials found that MR-107A-02 significantly reduced pain intensity following herniorrhaphy and bunionectomy surgeries compared to placebo.

Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.

The pharma tech company announced a deal with Starvision to roll out its services across the network over the next five years.

The growing complexity of supply chains necessitates the adoption of collaborative planning processes and capabilities such as S&OP and S&OE.